<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>
	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/content.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/print.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/font-awesome.css">	

	<!-- Basic Page Needs
  ================================================== -->
    <script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Reproduction</title>
	<meta name="description" content="Course Notes for Reproduction">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0"/>

	<script>
	  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	  })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

	  ga('create', 'UA-40381402-3', 'auto');
	  ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="https://dl.dropboxusercontent.com/u/157117/Class%20References/favicon.png" type="image/png">

	<!-- iOS Icons
	================================================== -->
	<link href="https://dl.dropboxusercontent.com/u/157117/notes/resources/images/icon-iphone.png" rel="apple-touch-icon"/>
	<link href="https://dl.dropboxusercontent.com/u/157117/notes/resources/images/icon-ipad.png" rel="apple-touch-icon" sizes="76x76" />
	<link href="https://dl.dropboxusercontent.com/u/157117/notes/resources/images/icon-iphone-retina.png" rel="apple-touch-icon" sizes="120x120"/>
	<link href="https://dl.dropboxusercontent.com/u/157117/notes/resources/images/icon-ipad-retina.png" rel="apple-touch-icon" sizes="152x152" />
</head>
<body>
    <div id="home-overlay">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<div id="header-search-icon"><a id="header-search-button"><i class="fa fa-search"></i></a></div>
</div>
<div id="header-search-bar">
	<form class="search" action="http://www.schulichnotes.com/reproduction/search.html">
	<div><input type="text" value="Search Reproduction" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	</form>
</div>
<div id="overlay"><h1><a style="border:none;" href="http://www.schulichnotes.com/reproduction">Reproduction</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://www.schulichnotes.com"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://www.schulichnotes.com/reproduction/search.html">
	<div style="float: left;"><input type="text" value="Search Reproduction" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

<div class="course-index">
	<a href="http://www.schulichnotes.com/reproduction">Reproduction</a>
</div>

        <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">Monday, November 10</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/intro-reproduction.html">Introduction to Reproduction</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/embryology-female-reproductive-tract.html">Embryology of the Female Reproductive Tract</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/10/anatomy-female-reproductive-tract.html">Anatomy of the Female Reproductive Tract</a></li></ul>
		<li class="day">Tuesday, November 11</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/anatomy-perineum.html">Anatomy of the Perineum</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/functional-sexual-anatomy.html">Functional Sexual Anatomy</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/11/histology-pathology-female-male-reproductive-tract.html">Histology &amp; Pathology of Female &amp; Male Reproductive Tracts</a></li></ul>
		<li class="day">Wednesday, November 12</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/12/male-reproductive-physiology.html">Male Reproductive Physiology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/12/female-reproductive-physiology.html">Female Reproductive Physiology</a></li></ul>
		<li class="day">Thursday, November 13</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/13/introduction-gynecological-clinical-exam.html">Introduction to the Gynecological Clinical Exam</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/13/hpo-axis-menstrual-cycle.html">The HPO Axis and the Menstrual Cycle</a></li></ul>
		<li class="day">Friday, November 14</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/14/pharmacology-contraception.html">Pharmacology of Contraception</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/14/female-pelvis-anatomy-lab.html">Female Pelvis Anatomy Lab</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">Monday, November 17</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/17/TBL-small-group-notes.html">TBL Small Group Notes</a></li></ul>
		<li class="day">Tuesday, November 18</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/understanding-promoting-reproductive-health-behaviours.html">Understanding &amp; Promoting Reproductive Health Behaviours</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/approach-amenorrhea.html">Approach to Amenorrhea</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/approach-abnormal-bleeding.html">Approach to Abnormal Bleeding</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/18/perineum-anatomy-lab.html">Perineum Anatomy Lab</a></li></ul>
		<li class="day">Wednesday, November 19</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/19/approach-vulva-vagina-stis.html">An Approach to the Vulva, Vagina, &amp; STIs</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/19/approach-acute-chronic-pelvic-pain.html">An Approach to Acute &amp; Chronic Pelvic Pain</a></li></ul>
		<li class="day">Thursday, November 20</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/pathology-abnormal-bleeding.html">Pathology of Abnormal Bleeding</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/pathology-pelvic-pain.html">Pathology of Pelvic Pain</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/20/chsg-adolescent-amenorrhea.html">Child Health Small Groups &ndash; Adolescent Amenorrhea</a></li></ul>
		<li class="day">Friday, November 21</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/21/clinical-anatomy-review.html">Clinical Anatomy Review</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">Monday, November 24</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/summary-gynecologic-cancer.html">Summary of Gynecologic Cancer</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/cervical-cancer-screening.html">Cervical Cancer Screening</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/24/clinical-exam-cervix.html">Clinical Exam of the Cervix</a></li></ul>
		<li class="day">Tuesday, November 25</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/issues-perimenopause-menopause.html">Issues of Perimenopause &amp; Menopause</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/pelvic-organ-prolapse.html">Pelvic Organ Prolapse</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/25/approach-pathology-post-menopausal-bleeding.html">Approach to &amp; Pathology of Post-Menopausal Bleeding</a></li></ul>
		<li class="day">Wednesday, November 26</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/approach-pelvic-mass.html">Approach to a Pelvic Mass</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/family-physician-approach-breast-problems.html">A Family Physician's Approach to Common Breast Problems</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/gynecologic-tract-imaging.html">Gynecologic Tract Imaging</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/26/pathology-pelvic-mass.html">Pathology of a Pelvic Mass</a></li></ul>
		<li class="day">Thursday, November 27</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/breast-anatomy-histology.html">Breast Anatomy &amp; Histology</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/clinical-examination-breast.html">Clinical Examination of the Breast</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/27/breast-pathology.html">Breast Pathology</a></li></ul>
		<li class="day">Friday, November 28</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/breast-imaging.html">Breast Imaging</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/surgical-management-breast-cancer.html">Surgical Management of Breast Cancer</a></li><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/11/28/medical-management-breast-cancer.html">Medical Management of Breast Cancer</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Monday, December 1</li>
		<ul></ul>
		<li class="day">Tuesday, December 2</li>
		<ul></ul>
		<li class="day">Wednesday, December 3</li>
		<ul><li class="lecture"><a href="http://www.schulichnotes.com/reproduction/2014/12/03/approach-sexual-orientation.html">Approach to Sexual Orientation</a></li></ul>
		<li class="day">Thursday, December 4</li>
		<ul></ul>
		<li class="day">Friday, December 5</li>
		<ul></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Monday, December 8</li>
		<ul></ul>
		<li class="day">Tuesday, December 9</li>
		<ul></ul>
		<li class="day">Wednesday, December 10</li>
		<ul></ul>
		<li class="day">Thursday, December 11</li>
		<ul></ul>
		<li class="day">Friday, December 12</li>
		<ul></ul>
	</ul>
	<li class="week">Week 6</li>
	<ul>
		<li class="day">Monday, December 15</li>
		<ul></ul>
		<li class="day">Tuesday, December 16</li>
		<ul></ul>
		<li class="day">Wednesday, December 17</li>
		<ul></ul>
		<li class="day">Thursday, December 18</li>
		<ul></ul>
	</ul>
</nav>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
            <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Pharmacology of Contraception</h1></div>
                <info datetime="2014-11-14">
                    <span class="author"><a href="http://www.schulichnotes.com/about.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Friday, November 14, 2014</span>
                </info>
                <div class="body"><ul>
  <li>We’ll be discussing the pharmacology of:
    <ol>
      <li><em>Estrogens</em>.</li>
      <li><em>Progestins</em>.</li>
      <li><em>GnRH analogs</em>.</li>
    </ol>
  </li>
</ul>

<h1 id="estrogens">Estrogens</h1>
<hr />

<ul>
  <li>In females, estrogens are produced by <em>granulosa cells</em> in the <em>ovarian follicle</em>.</li>
  <li>In males, estrogens are produced by <em>leydig cells</em> in the <em>testes</em> (converted from testosterone).</li>
  <li>In both sexes, estrogens are synthesized in the <em>adrenal cortex</em>.</li>
  <li>For a summary of steroid synthesis, see below.</li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/u/157117/Class%20References/1024px-Steroidogenesis.svg.png" /></p>

<p><img class="right" src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/tbdya6ts.png" /></p>

<h4 id="the-effect-of-gonadotropins-on-males"><strong>The Effect of Gonadotropins on Males</strong></h4>
<ol>
  <li><em>LH</em> stimulates <em>leydig cells</em> to produce <em>Testosterone</em>.</li>
  <li>FSH stimulates <em>sertoli cells</em> to produce <em>Androgen Binding Protein</em> (ABP).</li>
  <li>Testosterone then binds to ABP.</li>
</ol>

<h4 id="the-effect-of-gonadotropins-on-females"><strong>The Effect of Gonadotropins on Females</strong></h4>
<ol>
  <li><em>LH</em> stimulates <em>theca cells</em> to produce <em>androgens</em> (mainly androstenedione).</li>
  <li><em>FSH</em> stimulates <em>granulosa cells</em> to upregulate <em>aromatase activity</em>. This increases estrogen synthesis from the androgens.</li>
</ol>

<h2 id="secretion-of-estrogens"><strong>Secretion of Estrogens</strong></h2>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/b4f5lfze.png" />
<code>Descriptions of what's going on at every step are shown below.</code></p>

<ul>
  <li><em>A</em> → A <em>hypothalamic pulse generator</em> in the arcuate nucleus of the hypothalamus fires neuronal signals in a pulsed rhythm.</li>
  <li><em>B</em> → This results in the hypothalamic release of <em>pulsatile GnRH</em>.
    <ul>
      <li>GnRH neurons are inhibited by opioids, dopamine, and GABA-ergic stimulation (as we saw in &lt;a href=”http://www.schulichnotes.com/endocrinology”)&gt;&lt;/a&gt;.</li>
      <li>GnRH neurons are stimulated by noradrenergic neurons.</li>
    </ul>
  </li>
  <li><em>C</em> → pulsatile GnRH results in pulsatile LH and FSH.</li>
  <li><em>D</em> → this leads to pulsatile hormone levels in the plasma.</li>
  <li><em>E</em> → FSH and LH regulate ovarian production of estrogen and progesterone. These cause <em>negative feedback</em> via the inhibitory signals described above.</li>
  <li>For a description of hormone secretion during the ovarian cycle, please read <a href="http://www.schulichnotes.com/reproduction//2014/11/13/hpo-axis-menstrual-cycle.html">HPO Axis and the Menstrual Cycle</a>.
    <ul>
      <li>Especially remember that <em>progesterone rises in the luteal phase</em> (after ovulation).</li>
      <li>This becomes important later on when we’re discussing the use of progestins in hormonal contraceptives.</li>
    </ul>
  </li>
</ul>

<h2 id="mechanism-of-action"><strong>Mechanism of Action</strong></h2>
<ul>
  <li>Like all steroids, estrogens act by changing the expression of genes.</li>
  <li>They interact with <em>estrogen response elements</em> on specific genes.</li>
  <li>There are also some non-genomic targets → one example is how estrogen regulates Ca<sup>2+</sup> flux in granulosa cells.</li>
  <li>Estrogen metabolites such as <em>2-OH-estradiol</em> may be synthesized in the brain, and can function as <em>neurosteroids</em>.
    <ul>
      <li>Hence, estrogen metabolites have an effect on the brain.</li>
    </ul>
  </li>
</ul>

<h2 id="structure-activity-relationships"><strong>Structure Activity Relationships</strong></h2>
<ul>
  <li>Just like we saw with <a href="http://www.schulichnotes.com/endocrinology/2014/10/14/pharmacology-adrenal-glucocorticoids-mineralicorticoids-androgen-receptors.html">Pharmacology of Adrenal Hormones and Steroid Receptors</a>, <em>estradiol can be structurally modified to change its effects.</em></li>
  <li>These have been useful in the development of synthetic steroids and estrogenic agents.</li>
  <li>Key points (<strong>which you don’t need to know</strong>) are listed below:
    <ul>
      <li>The (1) <em>oxygen at C3</em>, (2) <em>17-OH</em>, (3) the <em>methyl group at C18</em>, and (4) an <em>aromatic A ring</em> are <strong>required for estrogenic activity</strong>.
        <ul>
          <li>Addition of an ethinyl group at C17 enhances potency and oral absorption.</li>
          <li>Similarly, a methoxy group at C3 enhances oral absorption.</li>
        </ul>
      </li>
    </ul>
  </li>
  <li><em>The only thing that may be testable is that you need to have an <i>aromatic A ring</i> to be an estrogen</em>:
    <ul>
      <li>This makes sense when you think of the hormone that synthesizes estradiol → <em>aromat</em>ase.</li>
    </ul>
  </li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/ukw4nrsp.png" />
<code>Here you can see the essential elements of an estrogen in pink (the O at C3, the OH at C17, the CH3 at C18), as well as some common modifications shown in red.</code></p>

<ul>
  <li><em>Ethinyl estradiol</em> and <em>mestranol</em> are the primary synthetic estrogens that are currently used.</li>
  <li>One of the two will be found in almost all hormone contraceptives containing estrogen.</li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/9stw51kv.png" /></p>

<h2 id="uses-of-estrogens"><strong>Uses of Estrogens</strong></h2>
<ol>
  <li><strong>Ovarian dysgenesis</strong> → a form of primary hypogonadism.
    <ul>
      <li>Estrogens are useful in stimulating secondary sex changes.</li>
      <li>Androgens are useful in stimulating growth.</li>
    </ul>
  </li>
  <li><strong>Following Menopause (HRT)</strong>
    <ul>
      <li>Can often alleviate some of the estrogen related symptoms of menopause (hot flashes, chils, sweating, etc).</li>
    </ul>
  </li>
  <li><strong>Osteoporosis</strong>
    <ul>
      <li>The risk of osteoporosis increases significantly after menopause, because, as we’ve seen before, estrogen binds the RANK ligand, which would otherwise stimulate ostoclast activity.</li>
      <li>By giving external estrogen, you can ameliorate this.</li>
      <li>The benefit may only be transient → ~1 year.</li>
    </ul>
  </li>
  <li><strong>Dysmenorrhea</strong>
    <ul>
      <li>Estrogens can be useful (often combined with a progestin in the form of an OCP, when used for this).</li>
    </ul>
  </li>
  <li><strong>Acne</strong>
    <ul>
      <li>Estrogens are useful (in females).</li>
      <li>Hence OCPs often help with acne.</li>
    </ul>
  </li>
  <li><strong>Hirsutism</strong></li>
  <li><strong>Control of Fertility</strong>
    <ul>
      <li><em>Most common use of estrogen</em>, in hormonal contraceptives.</li>
      <li>Often combined with a progestin (combined-OCP).</li>
    </ul>
  </li>
</ol>

<h2 id="estrogen-antagonists"><strong>Estrogen ‘Antagonists’</strong></h2>
<ul>
  <li><strong>SERMs</strong> → <em>Selective Estrogen Receptor Modulators</em>.
    <ul>
      <li>Generally end in ‘__phene’ (Raloxiphene, Clomiphene) or ‘__fen’ (Tamoxifen).</li>
    </ul>
  </li>
  <li>These are not really antagonists per se → SERMs may do anything from activate to block specific estrogen receptors.
    <ul>
      <li>However, clinically, they are often used as such.</li>
    </ul>
  </li>
  <li>Examples include:
    <ol>
      <li><strong>Tamoxifen</strong> → used in <em>estrogen dependent tumours</em>, although there is an <em>increased risk of endometrial cancer</em>. Hence, you have to weigh the risks and benefits.</li>
      <li><strong>Raloxiphene</strong> → similar to tamoxifen, except that it has a <em>lower risk of endometrial cancer</em> in comparison to tamoxifen.</li>
    </ol>
  </li>
  <li>SERMs may simultaneously up-regulate and down-regulate estrogen receptor activity at different locales.</li>
  <li>Below is a table showing the tissue specific agonist and antagonist activities of Tamoxifen and Raloxiphene.</li>
</ul>

<blockquote>
  <h4 id="agonist-and-antagonist-activity-of-serms"><strong>Agonist and Antagonist Activity of SERMs</strong></h4>

  <table>
    <thead>
      <tr>
        <th style="text-align: left"> </th>
        <th>Breast</th>
        <th>Endometrium</th>
        <th>Bone</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td style="text-align: left">Estrogen</td>
        <td>+++</td>
        <td>+++</td>
        <td>+++</td>
      </tr>
      <tr>
        <td style="text-align: left">Tamoxifen</td>
        <td>-</td>
        <td>+</td>
        <td>+</td>
      </tr>
      <tr>
        <td style="text-align: left">Raloxifene</td>
        <td>-</td>
        <td>-</td>
        <td>++</td>
      </tr>
    </tbody>
  </table>
</blockquote>

<ul>
  <li><strong>How do these tissue selective differences in function arise?</strong>
    <ul>
      <li>Different gene expression requires different combinations of cofactors.</li>
      <li>SERMs affect binding of certain cofactors to the estrogen receptor, but not others.</li>
      <li>In tissues where other cofactors can still bind the estrogen receptor, you still have some partial function → hence this is a <em>partial agonist</em>.</li>
      <li>In tissues where there are no other cofactors, you have no downstream function → hence this is an <em>antagonist</em>.</li>
    </ul>
  </li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/x9k720nj.png" /></p>

<ul>
  <li>Recall that <em>full agonists</em> are drugs that reach maximal binding and activation. 
    <ul>
      <li>This can be seen in the bottom left (the drug names aren’t important).</li>
      <li>Full agonists may vary in <i>potency</i> (the dose required for maximal effect), but their maxima is the same.</li>
    </ul>
  </li>
  <li><em>Partial agonists</em> don’t reach this maximum.
    <ul>
      <li>Examples of this are shown in the bottom right.</li>
    </ul>
  </li>
  <li><em>Antagonists</em> would be represented by a straight line.</li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/iwzqc_4v.png" /></p>

<h2 id="other-estrogen-related-drugs"><strong>Other Estrogen-related Drugs</strong></h2>
<ol>
  <li><strong>Aromatase Inhibitors</strong>
    <ul>
      <li>Example → <strong>Anastrozol</strong> (<em>Arimidex</em>).</li>
      <li>Used in women that are resistant to SERMs.</li>
      <li>Instead of affecting estrogen receptor activity (SERMs), you instead affect conversion of estrone and testosterone into estradiol via aromatase.</li>
    </ul>
  </li>
  <li><strong>Clomiphene</strong>
    <ul>
      <li>A <em>SERM</em> (hence __phene) that’s used as to <em>stimulate ovulation</em>.</li>
      <li>The mechanism for this is decreased feedback inhibition on GnRH, and hence, gonadotropin release.</li>
      <li><em>Can result in multiple ovulation</em> → increased frequency of triplets, quadruplets, etc.</li>
    </ul>
  </li>
</ol>

<h1 id="progestins">Progestins</h1>
<hr />

<ul>
  <li><em>What’s the difference between ‘Progestin’ and ‘Progesterone’?</em>
    <ul>
      <li><strong>They’re the same.</strong></li>
      <li>The conflict arose because two different groups discovered the hormone → one named it <em>progestin</em>, and the other named it <em>luteosterone</em>.</li>
      <li>They ended up agreeing to meet halfway on the name, and call the hormone <em>progesterone</em>.</li>
    </ul>
  </li>
</ul>

<h2 id="synthetic-progestins"><strong>Synthetic Progestins</strong></h2>
<ul>
  <li>Synthetic progestins are based on either (1) <em>progesterone</em> or (2) <em>19-<i>nor</i>testosterone</em>.
    <ul>
      <li>The <i>nor</i> refers to the fact that the C19 that’s normally on the steroid is missing.</li>
    </ul>
  </li>
  <li>In addition to their progestin activity, these can exhibit weak <em>androgenic</em> or <em>estrogenic</em> properties.
    <ul>
      <li>For instance, 19-nortestosteorne derivatives have some androgenic cross-reactivity.</li>
      <li>Some newer 19-nor derivatives have an additional modification (the addition of a 13-ethyl group), which eliminates the androgenic effects. Hence, they’re referred to as <em>impeded androgens</em>.</li>
    </ul>
  </li>
  <li><em>One example of an impeded androgen is</em> <strong>desogestrel</strong>.
    <ul>
      <li>Collectively, <em>impeded androgens are known as</em> <strong>gonanes</strong>.</li>
      <li>Another example of an impeded androgen is <em>levonorgestrel</em>, which is the progestin used in <em>Plan B</em>.</li>
    </ul>
  </li>
</ul>

<p><img src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/d58k5ch4.png" /></p>
<p><code>Some synthetic progestins. The ones on the top are derivatives of progesterone; the ones on the bottom are derivatives of 19-nortestosterone. The bottom row has <b>impeded estrogens</b>; note that they have that 13-ethyl group.</code></p>

<h2 id="uses-of-progestins"><strong>Uses of Progestins</strong></h2>
<ol>
  <li><strong>Dysfunctional uterine bleeding</strong>.
    <ul>
      <li>Progestin is useful. It’s given for 4-5 days and is then withdrawn.</li>
      <li>The idea here is that the withdrawal bleeding will ‘resynchronize’ the system.</li>
    </ul>
  </li>
  <li><strong>Endometriosis</strong>
    <ul>
      <li>Progestins by themselves can cause regression of ectopic endometrial growth (recall that they’re responsible for the shedding of the endometrium).</li>
    </ul>
  </li>
  <li><strong>Endometrial Carcinoma</strong>
    <ul>
      <li>Progestins aren’t curative, they’re only <em>palliative</em> here.</li>
    </ul>
  </li>
  <li><strong>Premenstrual tension</strong>
    <ul>
      <li>Progestins useful in last 10 days of cycle to combat irritability, headache, mastalgia, malaise etc.</li>
    </ul>
  </li>
  <li><strong>Control of fertility</strong>
    <ul>
      <li>As with estrogens, fertility control is quantitatively the most common use for progestins.</li>
    </ul>
  </li>
</ol>

<h2 id="anti-progestins"><strong>Anti-Progestins</strong></h2>
<ul>
  <li>Recall that <em>SERMs</em> are (sort of) <em>anti-estrogens</em>.</li>
  <li>An example of an <em>anti-progestin</em> is <strong>Mifepristone</strong> (RU-486).
    <ul>
      <li><em>Mifeprostone</em> is a weak partial agonist to the progesterone receptor, with mostly antagonist acrtivity.</li>
      <li>It’s a 19-<i>nor</i>steroid, that doesn’t have the 13-ethyl group (hence it’s not an impeded estrogen).</li>
      <li>It’s principally used as an <strong>abortifacient</strong> (usually along with <em>misoprostol</em>, which we saw from GI, was a <em>prostaglandin analogue</em>).</li>
    </ul>
  </li>
</ul>

<h2 id="pharmacological-approaches"><strong>Pharmacological Approaches</strong></h2>
<ul>
  <li>Progestin can be used in fertility treatment in the following ways:
    <ol>
      <li><strong>Sequentially with Estrogen</strong> (NOT USED ANYMORE) → ie. 14 days of estrogen, followed by 6 days of progesterone.
        <ul>
          <li>Only for historical interest; the 2 weeks of unapposed estrogen caused side-effects.</li>
        </ul>
      </li>
      <li><strong>Combined administration</strong> → estrogen + progesterone for 21 days; nothing for 7 days.
        <ul>
          <li>This is what you see with the <em>combined OCPs</em>.</li>
        </ul>
      </li>
      <li><strong>Progestin only</strong> → continuous administration of progesterone.
        <ul>
          <li>This is what you see with the <em>progesterone only pills</em> (POPs).</li>
        </ul>
      </li>
    </ol>
  </li>
  <li>With a combined OCP, the <em>estrogenic component inhibits FSH</em>, and the <em>progestin component inhibits LH</em>.</li>
</ul>

<h2 id="effects-of-oral-contraceptives"><strong>Effects of Oral Contraceptives</strong></h2>
<ol>
  <li><strong>Ovaries</strong> → combination OCPs <em>inhibit follicular development</em>, and may cause the ovaries to decrease in size. Normal function usually returns after OCP therapy is stopped.</li>
  <li><strong>Uterus</strong> → <em>cervical hypertrophy</em> occurs with prolonged use.
    <ul>
      <li><em>Reduced bleeding</em> is also seen.</li>
    </ul>
  </li>
  <li><strong>Breasts</strong> → usually lead to <em>slight breast enlargement</em>.
    <ul>
      <li>As an interesting aside, <em>Bromocriptine</em> (which we saw was used to treat prolactinomas) is often given to women to suppress lactation if they’re giving their child up for adoption.</li>
    </ul>
  </li>
  <li><strong>Endocrine Function</strong> → estrogenic compounds increase <em>α-2 globulins.</em>
    <ul>
      <li>These include the hormone binding proteins → SBG, TBG, CBG, etc.</li>
    </ul>
  </li>
  <li><strong>Blood/VCS</strong> → <em>increased levels of clotting factors</em> (Factors VII, VIII, IX and X specifically).
    <ul>
      <li>With estrogens, there’s an increased risk of thromboembolic events → strokes, MIs, etc.</li>
    </ul>
  </li>
</ol>

<h2 id="adverse-effects-of-ocps"><strong>Adverse Effects of OCPs</strong></h2>

<h4 id="major-adverse-effects">Major Adverse Effects</h4>
<ul>
  <li><strong>Estrogens increase thromboembolic risks</strong>:
    <ol>
      <li><em>Venous thromboembolism</em>.</li>
      <li><em>Myocardial infarction</em>.</li>
      <li><em>Cerebrovascular disease</em>.</li>
      <li><em>Cholestatic jaundice</em>.</li>
    </ol>
  </li>
  <li><em>Depression</em> is also seen, although this may due to progestin (estrogens are more excitatory; recall that estrogen can be metabolized into neurosteroids in the brain).</li>
</ul>

<h4 id="minor-adverse-effects">Minor Adverse Effects</h4>
<ol>
  <li><em>Breakthrough bleeding</em> → especially with low dose OCPs.</li>
  <li><em>Weight Gain</em></li>
  <li><em>Chloasma</em> → irregular well demarcated hyperpigmented macules to patches commonly found on the upper cheek, nose, lips, upper lip, and forehead. Called the ‘mask of pregnancy’ if found in a pregnant woman.</li>
  <li><em>Nausea, mastalgia</em>.</li>
  <li><em>Hirsutism</em>.</li>
</ol>

<h2 id="beneficial-effects-of-ocps"><strong>Beneficial Effects of OCPs</strong></h2>
<ul>
  <li>Reduced risk of a lot of things, including ovarian cysts, ovarian and endometrial cancer, benign breast disease, pelvic inflammatory disease, duodenal ulcers, rheumatoid arthritis, dysmenorrhea, and endometriosis.</li>
</ul>

<h2 id="ocp-preparations"><strong>OCP Preparations</strong></h2>
<ul>
  <li>Combined OCPs can be (1) <em>monophasic</em>, (2) <em>biphasic</em>, or (3) <em>triphasic</em>.
    <ul>
      <li>The ‘phases’ typically refer to the progesterone level; the estrogen level remains constant over the 21 days, but the progesterone levels will fluctuate.</li>
      <li>The idea of having a more phasic release of progesterone is to better match the endogenous release of progesterone (where it rises in the luteal phase).</li>
    </ul>
  </li>
  <li>Progesterone only Pills (POPs) are slightly less effective, but can be used in patients that have estrogen-related contraindications.</li>
</ul>

<h2 id="bioavailability-of-synthetic-estrogens"><strong>Bioavailability of Synthetic Estrogens</strong></h2>
<ul>
  <li><strong>Antibiotics affect the bioavailability of OCPs</strong>:
    <ul>
      <li>This is because estrogens are made bioavailable by the intestinal flora.</li>
      <li>The intestinal flora cleaves conjugated estrogens into unconjugated estrogens, which are then bioavailable.</li>
      <li><em>Antibiotic therapy reduces the enteric flora enough to affect the bioavailability of estrogen</em>.</li>
    </ul>
  </li>
</ul>

<h1 id="gnrh-analogs">GnRH Analogs</h1>
<hr />

<p><img class="right" src="https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/6xp1e9r5.png" /></p>

<ul>
  <li>GnRH is a decapeptide called <strong>gonadorelin</strong> which is released in a pulsatile manner and acts to trigger the secretion of FSH and LH.
    <ul>
      <li>It’s synthesized in the arcuate nucleus of the hypothalamus. </li>
    </ul>
  </li>
  <li>We saw before that GnRH analogs are used to treat <em>precocious puberty</em> (in <a href="http://www.schulichnotes.com/endocrinology">Endocrinology</a>).
    <ul>
      <li>This was because the continuous secretion of GnRH causes a downregulation of GnRH receptors on the pituitary.</li>
      <li>Of course, this means that there will be a transient exacerbation of gonadotropin release, before the downregulation occurs.</li>
    </ul>
  </li>
  <li><em>Examples of GnRH Analogs</em> (Note that they generally end in ‘__relin’):
    <ol>
      <li><em>Leuprolide</em>.</li>
      <li><em>Naferelin</em>.</li>
      <li><em>Goserelin</em>.</li>
      <li><em>Histrelin</em>.</li>
    </ol>
  </li>
</ul>

<h2 id="uses-of-gnrh-analogs"><strong>Uses of GnRH Analogs</strong></h2>
<ul>
  <li>GnRH analogs can <em>stimulate gonadotropin release</em> if administered in pulses, or <em>inhibit gonadotropin release</em> if administered continously.
    <ul>
      <li>A programmable pump can be used to administer GnRH in pulses.</li>
    </ul>
  </li>
  <li><em>Uses when administered in pulses</em> (↑ LH, FSH):
    <ul>
      <li>Infertility (namely hypothalamic hypogonadotropic hypogonadism).</li>
      <li>In vitro fertilization.</li>
    </ul>
  </li>
  <li><em>Uses when administered continously</em> (↓ LH, FSH):
    <ul>
      <li>Prostate cancer.</li>
      <li>Endometriosis.</li>
      <li>Polycystic ovary syndrome.</li>
      <li>Precocious puberty.</li>
    </ul>
  </li>
  <li>When used to inhibit gonadotropins, the transient phase where GnRH receptors have yet to be downregulated can be a problem.
    <ul>
      <li>This can be seen in prostate cancer for instance, where GnRH analogs can cause ‘flares’ in the short term.</li>
      <li>To prevent this, an anti-androgen such as flutamide is used to ‘cover’ the gonadotropin effect over this time period.</li>
    </ul>
  </li>
</ul>
                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://www.schulichnotes.com/reproduction/2014/11/13/hpo-axis-menstrual-cycle.html"><i class="fa fa-angle-left"></i> The HPO Axis and the Menstrual Cycle</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://www.schulichnotes.com/reproduction/2014/11/14/female-pelvis-anatomy-lab.html">Female Pelvis Anatomy Lab <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://www.schulichnotes.com/reproduction/index.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/search.css">	
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/classie.js" type="text/javascript"></script>
<script>
var search = document.getElementById('header-search-icon');
var searchbar = document.getElementById('header-search-bar');
search.onclick = function(){classie.toggle(searchbar, 'search-bar-open');}
$(document).ready(function() {$('#tipue_search_input').tipuesearch();});
</script>
</body>
</html>